Rethinking medulloblastoma from a targeted therapeutics perspective

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Medulloblastoma is a challenging central nervous system tumor with potential for cure.
• Identifying therapeutic targets is crucial for improving treatment strategies.

Purpose of the Study:

• To comprehensively profile medulloblastoma for overexpressed proteins and genetic alterations.
• To identify potential therapeutic targets and assess immune checkpoint inhibitor relevance.

Main Methods:

• Multiplatform analysis of 36 medulloblastomas (2009-2015).
• Techniques included immunohistochemistry, next-generation sequencing, and in situ hybridization.
• Evaluated protein expression, immune checkpoint markers, mutations, tumor mutational load, and gene amplifications.

Main Results:

• High expression of MRP1, TUBB3, PTEN, TOP2A, thymidylate synthase (TS), RRM1, and TOP1 was observed.
• TOP1 was enriched in metastatic tumors; TOP2A and TOP1 expression correlated positively.
• Immune checkpoint markers (PD-1, PD-L1) and tumor mutational load were low, suggesting limited efficacy for monotherapy inhibitors.

Conclusions:

• Frequently expressed targets like MRP1 and TOP1 have available therapeutics.
• These findings support the consideration of targeted therapies for medulloblastoma treatment.